title: Ingested (oral) SIRS peptide 1-21 inhibits acute EAE by inducing Th2-like cytokines.
abstract: OBJECTIVE
  Ingested type I IFN inhibits clinical attacks, relapses and inflammation in murine chronic relapsing EAE by inhibiting Th1-like cytokines. Type I IFN activates human suppressor T cells that produce SIRS.
  
  
  METHODS
  We examined whether oral (ingested) SIRS peptide inhibits EAE by decreasing Th1-like cytokines.
  
  
  RESULTS
  Parenteral SIRS peptide 1-21 showed a significant inhibition of disease severity in murine EAE. Ingested SIRS peptide at 10 and 100 microg SIRS peptide showed a significant inhibition of disease severity but also a prolonged delay in the onset of disease compared to placebo. There were significantly less inflammatory foci in the SIRS peptide fed group compared to the control mock fed group. Splenocytes from SIRS peptide 1-21 fed mice showed increased production of Th2-like CD30L, IL-13, TCA-3 cytokines/chemokines and decreased production of Th1-like cytokine lymphotactin.
  
  
  CONCLUSIONS
  Ingested (oral) SIRS peptide significantly inhibits both clinical EAE and inflammation predominately via counter-regulatory type 2-like cytokines/chemokines IL-13, CD30L and TCA-3.
authors.affiliation: Department of Neurology, University of Texas-Houston, Health Science Center, 6431 Fannin St, Houston, TX 77030, USA. staley.a.brod@uth.tmc.edu
authors.forename: Staley A
authors.initials: SA
authors.lastname: Brod
authors.forename: Zachary
authors.initials: Z
authors.lastname: Hood
mesh_terms: D000284:Administration, Oral; D019264:Adoptive Transfer / Q000379:methods; D000818:Animals; D016207:Cytokines / Q000378:metabolism*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004306:Dose-Response Relationship, Immunologic; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000188:drug therapy*; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects*; D051379:Mice; D008810:Mice, Inbred C57BL; D010455:Peptides / Q000008:administration & dosage*; D013491:Suppressor Factors, Immunologic / Q000008:administration & dosage / Q000737:chemistry*; D013997:Time Factors
chemical_list: D016207:Cytokines; D010455:Peptides; D013491:Suppressor Factors, Immunologic; C013256:soluble immune response suppressor